Kalpalatha Guntupalli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kalpalatha Guntupalli has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Dilip R. Karnad
Department of Critical Care, Jupiter Hospital, Thane, India
2 shared publicationsMichael Belfort
Department of Medicine, the Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX; Department of Surgery, Baylor College of Medicine, Houston, TX; Department of Anesthesiology, Baylor College of Medicine, Houston, TX; Department of Obstetrics and Gynecology, Texas Children's Hospital Pavilion for Women, Houston, TX
2 shared publicationsNicole Hall
Department of Medicine, the Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX; Department of Obstetrics and Gynecology, Texas Children's Hospital Pavilion for Women, Houston, TX
2 shared publicationsVenkata Bandi
Section of Pulmonary, Critical Care, and Sleep Medicine, Baylor College of Medicine, Houston, TX
2 shared publicationsAniket Shitalkumar Rali
Baylor Coll Med, Dept Internal Med, Div Pulm Crit Care & Sleep Med, Houston, TX 77030 USA
1 shared publication- Archana Ayyar
Department of Obstetrics and Gynecology, Baylor College of Medicine, USA
1 shared publication
Latest Publications
- Open Access
- 2 March 2022
- Published by Hindawi Limited in Case Reports in Obstetrics and Gynecology
- Vol. 2022, 1-4
Management of a Novel Autoimmune Disease, COPA Syndrome, in Pregnancy
Background. COPA syndrome is a rare autoimmune disease, demonstrating an autosomal dominant inheritance pattern with variable penetration that occurs more frequently in females than males. This disease manifests in childhood as pulmonary hemorrhage, arthritis, and renal disease. Case. We present a case of obstetric management of a 20-year-old nulligravida patient with a diagnosis of COPA syndrome. Her case was further complicated by multiple antepartum admissions for hypoxemia and a complex psychosocial history of substance use. On her first antepartum admission, rheumatology recommended management with hydroxychloroquine, inhaled corticosteroids (budesonide), and bronchodilators (albuterol inhaler) as needed. On admission for induction of labor, she was again noted to have oxygen desaturations. A chronic thrombus was noted on computed tomography (CT), and a multidisciplinary team was recommended against Valsalva. Thus, she had a primary cesarean delivery. Her postpartum course was only remarkable for improved oxygenation status. Conclusion. Management of COPA syndrome should be performed by a multidisciplinary team including maternal-fetal medicine, rheumatology, and pulmonology specialists. Traditionally, COPA syndrome is treated with immunomodulator therapy often used to treat autoimmune syndromes. However, many of these medications are not well studied or contraindicated in pregnancy. Preconception counseling is recommended both to ensure pregnancy safe medications being prescribed and to provide information on the genetic inheritance of this disease. At time of entry to care, patients should have a baseline work-up including a radiographic imaging, complete blood count, complete metabolic panel, lactate dehydrogenase, and a 24-hour urine protein collection for baseline. Although thought to be rare, COPA syndrome has an autosomal dominance pattern of inheritance with variable penetrance that is more common in females. Thus, incidence of COPA syndrome in pregnancy will likely increase in the future. Further case studies are warranted to optimize management of patients with COPA syndrome in pregnancy.
- 2 March 2022
- Published by Hindawi Limited in Case Reports in Obstetrics and Gynecology
- Vol. 2022, 1-4
Open AccessManagement of a Novel Autoimmune Disease, COPA Syndrome, in Pregnancy
Background. COPA syndrome is a rare autoimmune disease, demonstrating an autosomal dominant inheritance pattern with variable penetration that occurs more frequently in females than males. This disease manifests in childhood as pulmonary hemorrhage, arthritis, and renal disease. Case. We present a case of obstetric management of a 20-year-old nulligravida patient with a diagnosis of COPA syndrome. Her case was further complicated by multiple antepartum admissions for hypoxemia and a complex psychosocial history of substance use. On her first antepartum admission, rheumatology recommended management with hydroxychloroquine, inhaled corticosteroids (budesonide), and bronchodilators (albuterol inhaler) as needed. On admission for induction of labor, she was again noted to have oxygen desaturations. A chronic thrombus was noted on computed tomography (CT), and a multidisciplinary team was recommended against Valsalva. Thus, she had a primary cesarean delivery. Her postpartum course was only remarkable for improved oxygenation status. Conclusion. Management of COPA syndrome should be performed by a multidisciplinary team including maternal-fetal medicine, rheumatology, and pulmonology specialists. Traditionally, COPA syndrome is treated with immunomodulator therapy often used to treat autoimmune syndromes. However, many of these medications are not well studied or contraindicated in pregnancy. Preconception counseling is recommended both to ensure pregnancy safe medications being prescribed and to provide information on the genetic inheritance of this disease. At time of entry to care, patients should have a baseline work-up including a radiographic imaging, complete blood count, complete metabolic panel, lactate dehydrogenase, and a 24-hour urine protein collection for baseline. Although thought to be rare, COPA syndrome has an autosomal dominance pattern of inheritance with variable penetrance that is more common in females. Thus, incidence of COPA syndrome in pregnancy will likely increase in the future. Further case studies are warranted to optimize management of patients with COPA syndrome in pregnancy.
- 7 July 2020
- Published by Jaypee Brothers Medical Publishing in Indian Journal of Respiratory Care
- Vol. 9 (2) , 134-140
High-flow Nasal Cannula: COVID 19 and Beyond
- 7 July 2020
- Published by Jaypee Brothers Medical Publishing in Indian Journal of Respiratory Care
- Vol. 9 (2) , 134-140
High-flow Nasal Cannula: COVID 19 and Beyond
- 1 September 2018
- Published by Elsevier in Sleep Medicine Clinics
- Vol. 13 (3) , 349-357
Sleep-Disordered Breathing in Pregnancy
- 1 September 2018
- Published by Elsevier in Sleep Medicine Clinics
- Vol. 13 (3) , 349-357
Sleep-Disordered Breathing in Pregnancy
- 4 April 2017
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 166 (7) , W40-W43
Update in Pulmonary Medicine: Evidence Published in 2016
- 4 April 2017
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 166 (7) , W40-W43
Update in Pulmonary Medicine: Evidence Published in 2016
- 3 May 2016
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 164 (9) , W55-W60
Update in Pulmonary Medicine: Evidence Published in 2015
- 3 May 2016
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 164 (9) , W55-W60
Update in Pulmonary Medicine: Evidence Published in 2015
- 1 January 2012
- Published by Springer Nature
- p. 1803-1815
Pregnancy, Infectious Complications
- Open Access
- 30 June 2010
- Published by Springer Nature in Critical Care
- Vol. 14 (3) , R125
A multi-center, randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for the treatment of fever in critically ill and non-critically ill adults
Introduction: Hospitalized patients are often unable to ingest or tolerate oral antipyretics and recently an aqueous formulation of intravenous (IV) ibuprofen was approved by the US-FDA for the reduction of fever in adults. Methods: We evaluated IV ibuprofen to reduce fever exceeding 101.0°F, measured as the percentage of subjects achieving a temperature P = 0.0264; 200 mg IV ibuprofen n = 21/30 (70%) P = 0.0043; 400 mg IV ibuprofen n = 24/31 (77%) P = 0.0005. A total of 53/120 patients (44%) were prospectively defined as critically ill at baseline and similar temperature reductions were observed in this subgroup. There were no statistically significant differences between treatment groups or when compared to placebo in transfusion, bleeding, renal failure or mortality. Conclusions: All doses of IV ibuprofen tested reduced fever at four hours and throughout the first 24 hours of dosing. The 400 mg dose was effective in lowering temperature to normal and maintaining this over the first 24 hours of dosing. IV ibuprofen was effective in reducing fevers in critically ill and non-critically ill groups. Following 24 hours of administration of IV ibuprofen, no clinically significant differences in any safety parameter including renal function or bleeding occurred through the 28-day follow-up period. Trial registrations: Clinicaltrials.gov registration number: NCT01131000.
- 30 June 2010
- Published by Springer Nature in Critical Care
- Vol. 14 (3) , R125
Open AccessA multi-center, randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for the treatment of fever in critically ill and non-critically ill adults
Introduction: Hospitalized patients are often unable to ingest or tolerate oral antipyretics and recently an aqueous formulation of intravenous (IV) ibuprofen was approved by the US-FDA for the reduction of fever in adults. Methods: We evaluated IV ibuprofen to reduce fever exceeding 101.0°F, measured as the percentage of subjects achieving a temperature P = 0.0264; 200 mg IV ibuprofen n = 21/30 (70%) P = 0.0043; 400 mg IV ibuprofen n = 24/31 (77%) P = 0.0005. A total of 53/120 patients (44%) were prospectively defined as critically ill at baseline and similar temperature reductions were observed in this subgroup. There were no statistically significant differences between treatment groups or when compared to placebo in transfusion, bleeding, renal failure or mortality. Conclusions: All doses of IV ibuprofen tested reduced fever at four hours and throughout the first 24 hours of dosing. The 400 mg dose was effective in lowering temperature to normal and maintaining this over the first 24 hours of dosing. IV ibuprofen was effective in reducing fevers in critically ill and non-critically ill groups. Following 24 hours of administration of IV ibuprofen, no clinically significant differences in any safety parameter including renal function or bleeding occurred through the 28-day follow-up period. Trial registrations: Clinicaltrials.gov registration number: NCT01131000.